TEST BANK
Karch's Focus on Nursing Pharmacology, 10th Edition
Rebecca Tucker | Chapters 160 | Volume A
1,200 Original Questions • Correct Answer After Every Question • Detailed Teaching Rationale
Page 1
,Coverage
• Chapter 1: Introduction to Drugs
• Chapter 2: Pharmacodynamics and Pharmacokinetics
• Chapter 3: Adverse Reactions to Drugs
• Chapter 4: The Nursing Process and Clinical Judgment Measurement Model Informing Drug Therapy
and Patient Safety
• Chapter 5: Drug Administration and Dosage Calculations
• Chapter 6: Challenges to Safe and Effective Drug Therapy
• Chapter 7: Introduction to Cell Physiology
• Chapter 8: AntiInfective Agents
• Chapter 9: Antibiotics
• Chapter 10: Antiviral Agents
• Chapter 11: Antifungal Agents
• Chapter 12: Antiprotozoal Agents
• Chapter 13: Anthelmintic Agents
• Chapter 14: Antineoplastic Agents
• Chapter 15: Introduction to the Immune Response and Inflammation
• Chapter 16: Antiinflammatory, Antiarthritis, and Related Agents
• Chapter 17: Immune Modulators
• Chapter 18: Vaccines and Sera
• Chapter 19: Introduction to Nerves and the Nervous System
• Chapter 20: Anxiolytic and Hypnotic Agents
• Chapter 21: Antidepressant Agents
• Chapter 22: Psychotherapeutic Agents
• Chapter 23: Antiseizure Agents
• Chapter 24: Antiparkinsonism Agents
• Chapter 25: Muscle Relaxants
• Chapter 26: Pain Management and Substance Use Disorder Treatment
• Chapter 27: General and Local Anesthetic Agents
• Chapter 28: Neuromuscular Junction Blocking Agents
• Chapter 29: Introduction to the Autonomic Nervous System
• Chapter 30: Adrenergic Agonists
Page 2
,• Chapter 31: Adrenergic Antagonists
• Chapter 32: Cholinergic Agonists
• Chapter 33: Anticholinergic Agents
• Chapter 34: Introduction to the Endocrine System
• Chapter 35: Hypothalamic and Pituitary Agents
• Chapter 36: Adrenocortical Agents
• Chapter 37: Thyroid and Parathyroid Agents
• Chapter 38: Agents to Control Blood Glucose Levels
• Chapter 39: Introduction to the Reproductive System
• Chapter 40: Drugs Affecting the Female Reproductive System
• Chapter 41: Drugs Affecting the Male Reproductive System
• Chapter 42: Introduction to the Cardiovascular System
• Chapter 43: Drugs Affecting Blood Pressure
• Chapter 44: Agents for Treating Heart Failure
• Chapter 45: Antiarrhythmic Agents
• Chapter 46: Antianginal Agents
• Chapter 47: LipidLowering Agents
• Chapter 48: Drugs Affecting Blood Coagulation
• Chapter 49: Drugs Used to Treat Anemias
• Chapter 50: Introduction to the Renal System
• Chapter 51: Agents Affecting Body Fluid Volume and Components
• Chapter 52: Drugs Affecting the Urinary Tract and the Bladder
• Chapter 53: Introduction to the Respiratory System
• Chapter 54: Drugs Acting on the Upper Respiratory Tract
• Chapter 55: Drugs Acting on the Lower Respiratory Tract
• Chapter 56: Introduction to the Gastrointestinal System
• Chapter 57: Drugs Affecting Gastrointestinal Secretions and Absorption
• Chapter 58: Drugs Affecting Gastrointestinal Motility
• Chapter 59: Antiemetic Agents
• Chapter 60: Vitamins, Minerals, and Complementary/Alternative Medications
Page 3
, Chapter 1: Introduction to Drugs
1. Which monitoring plan is most appropriate for a patient receiving half-life?
A. Time required for plasma concentration to decrease by about half during elimination.
B. Timing of levels for narrow-therapeutic index drugs.
C. Steady state often takes several half-lives.
D. Estimate drug accumulation and time to steady state.
Answer: B Timing of levels for narrow-therapeutic index drugs.
Rationale: Monitoring should target the desired response and predictable toxicities. For half-life, the
appropriate focus is: timing of levels for narrow-therapeutic index drugs. This connects pharmacology to
patient safety rather than substituting an indication, mechanism, or teaching statement for an actual
monitoring plan. Clinical reasoning: first identify exactly what the stem is testing—such as drug class,
mechanism, indication, expected effect, adverse reaction, contraindication, monitoring priority, or
patient teaching—then select the option that answers that dimension most directly. Safety connection:
the correct response links pharmacology knowledge to prevention of medication error, recognition of
toxicity or deterioration, and appropriate followup. Why the distractors are incorrect: some alternatives
describe a related pharmacologic property or safety principle, while others do not answer the clinical
dimension requested or conflict with safe medicationuse principles.
2. Which pair correctly matches pharmacokinetics with its drug class?
A. Pharmacokinetics vitamin K antagonist
B. Pharmacokinetics protonpump inhibitor
C. Pharmacokinetics loop diuretic
D. Pharmacokinetics general pharmacology concept
Answer: D Pharmacokinetics general pharmacology concept
Rationale: pharmacokinetics belongs to the general pharmacology concept category. Correct class
recognition helps predict mechanism, indications, interactions, and adverse effects. The distractor classes
have different pharmacologic targets and clinical uses. Clinical reasoning: first identify exactly what the
stem is testing—such as drug class, mechanism, indication, expected effect, adverse reaction,
contraindication, monitoring priority, or patient teaching—then select the option that answers that
dimension most directly. Safety connection: the correct response links pharmacology knowledge to
prevention of medication error, recognition of toxicity or deterioration, and appropriate followup. Why
the distractors are incorrect: some alternatives describe a related pharmacologic property or safety
principle, while others do not answer the clinical dimension requested or conflict with safe medication
use principles.
3. Which statement best describes the primary therapeutic use or clinical role of pharmacokinetics?
Page 4
Karch's Focus on Nursing Pharmacology, 10th Edition
Rebecca Tucker | Chapters 160 | Volume A
1,200 Original Questions • Correct Answer After Every Question • Detailed Teaching Rationale
Page 1
,Coverage
• Chapter 1: Introduction to Drugs
• Chapter 2: Pharmacodynamics and Pharmacokinetics
• Chapter 3: Adverse Reactions to Drugs
• Chapter 4: The Nursing Process and Clinical Judgment Measurement Model Informing Drug Therapy
and Patient Safety
• Chapter 5: Drug Administration and Dosage Calculations
• Chapter 6: Challenges to Safe and Effective Drug Therapy
• Chapter 7: Introduction to Cell Physiology
• Chapter 8: AntiInfective Agents
• Chapter 9: Antibiotics
• Chapter 10: Antiviral Agents
• Chapter 11: Antifungal Agents
• Chapter 12: Antiprotozoal Agents
• Chapter 13: Anthelmintic Agents
• Chapter 14: Antineoplastic Agents
• Chapter 15: Introduction to the Immune Response and Inflammation
• Chapter 16: Antiinflammatory, Antiarthritis, and Related Agents
• Chapter 17: Immune Modulators
• Chapter 18: Vaccines and Sera
• Chapter 19: Introduction to Nerves and the Nervous System
• Chapter 20: Anxiolytic and Hypnotic Agents
• Chapter 21: Antidepressant Agents
• Chapter 22: Psychotherapeutic Agents
• Chapter 23: Antiseizure Agents
• Chapter 24: Antiparkinsonism Agents
• Chapter 25: Muscle Relaxants
• Chapter 26: Pain Management and Substance Use Disorder Treatment
• Chapter 27: General and Local Anesthetic Agents
• Chapter 28: Neuromuscular Junction Blocking Agents
• Chapter 29: Introduction to the Autonomic Nervous System
• Chapter 30: Adrenergic Agonists
Page 2
,• Chapter 31: Adrenergic Antagonists
• Chapter 32: Cholinergic Agonists
• Chapter 33: Anticholinergic Agents
• Chapter 34: Introduction to the Endocrine System
• Chapter 35: Hypothalamic and Pituitary Agents
• Chapter 36: Adrenocortical Agents
• Chapter 37: Thyroid and Parathyroid Agents
• Chapter 38: Agents to Control Blood Glucose Levels
• Chapter 39: Introduction to the Reproductive System
• Chapter 40: Drugs Affecting the Female Reproductive System
• Chapter 41: Drugs Affecting the Male Reproductive System
• Chapter 42: Introduction to the Cardiovascular System
• Chapter 43: Drugs Affecting Blood Pressure
• Chapter 44: Agents for Treating Heart Failure
• Chapter 45: Antiarrhythmic Agents
• Chapter 46: Antianginal Agents
• Chapter 47: LipidLowering Agents
• Chapter 48: Drugs Affecting Blood Coagulation
• Chapter 49: Drugs Used to Treat Anemias
• Chapter 50: Introduction to the Renal System
• Chapter 51: Agents Affecting Body Fluid Volume and Components
• Chapter 52: Drugs Affecting the Urinary Tract and the Bladder
• Chapter 53: Introduction to the Respiratory System
• Chapter 54: Drugs Acting on the Upper Respiratory Tract
• Chapter 55: Drugs Acting on the Lower Respiratory Tract
• Chapter 56: Introduction to the Gastrointestinal System
• Chapter 57: Drugs Affecting Gastrointestinal Secretions and Absorption
• Chapter 58: Drugs Affecting Gastrointestinal Motility
• Chapter 59: Antiemetic Agents
• Chapter 60: Vitamins, Minerals, and Complementary/Alternative Medications
Page 3
, Chapter 1: Introduction to Drugs
1. Which monitoring plan is most appropriate for a patient receiving half-life?
A. Time required for plasma concentration to decrease by about half during elimination.
B. Timing of levels for narrow-therapeutic index drugs.
C. Steady state often takes several half-lives.
D. Estimate drug accumulation and time to steady state.
Answer: B Timing of levels for narrow-therapeutic index drugs.
Rationale: Monitoring should target the desired response and predictable toxicities. For half-life, the
appropriate focus is: timing of levels for narrow-therapeutic index drugs. This connects pharmacology to
patient safety rather than substituting an indication, mechanism, or teaching statement for an actual
monitoring plan. Clinical reasoning: first identify exactly what the stem is testing—such as drug class,
mechanism, indication, expected effect, adverse reaction, contraindication, monitoring priority, or
patient teaching—then select the option that answers that dimension most directly. Safety connection:
the correct response links pharmacology knowledge to prevention of medication error, recognition of
toxicity or deterioration, and appropriate followup. Why the distractors are incorrect: some alternatives
describe a related pharmacologic property or safety principle, while others do not answer the clinical
dimension requested or conflict with safe medicationuse principles.
2. Which pair correctly matches pharmacokinetics with its drug class?
A. Pharmacokinetics vitamin K antagonist
B. Pharmacokinetics protonpump inhibitor
C. Pharmacokinetics loop diuretic
D. Pharmacokinetics general pharmacology concept
Answer: D Pharmacokinetics general pharmacology concept
Rationale: pharmacokinetics belongs to the general pharmacology concept category. Correct class
recognition helps predict mechanism, indications, interactions, and adverse effects. The distractor classes
have different pharmacologic targets and clinical uses. Clinical reasoning: first identify exactly what the
stem is testing—such as drug class, mechanism, indication, expected effect, adverse reaction,
contraindication, monitoring priority, or patient teaching—then select the option that answers that
dimension most directly. Safety connection: the correct response links pharmacology knowledge to
prevention of medication error, recognition of toxicity or deterioration, and appropriate followup. Why
the distractors are incorrect: some alternatives describe a related pharmacologic property or safety
principle, while others do not answer the clinical dimension requested or conflict with safe medication
use principles.
3. Which statement best describes the primary therapeutic use or clinical role of pharmacokinetics?
Page 4
